Hutchmed China (HCM)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and...
- Open
- 12.600
- High
- 12.760
- Low
- 12.600
- Prev. Close
- 12.560
- Volume
- 31.82K
- Turnover
- 404.41K
- Avg Price
- 12.710
- Bid/Ask Ratio
- 24.22%
- Amplitude
- 1.27%
- 52wk High
- 18.300
- Volume Ratio
- 4.05
- Turnover Ratio
- 0.03%
Hutchmed China Analyst Rating
View moreForecast & Rating
Aug 12, 2026Price forecast
$20.9966.60%
Forecast & RatingBuy
13analysts
- Strong buy53.85%
- Buy15.38%
- Hold30.77%
- Sell0.00%
- Strong sell0.00%
News
- London Stock Exchange · 5 hours ago
REG - Hutchmed China Ltd - Announcement pursuant to AIM Rule 17 Schedule 2(g)
- AASTOCKS News · 6 hours ago
CICC Raises HUTCHMED TP to HKD26 on Bright Prospects for Overseas Filing of Savolitinib
- benzinga_article · 1 day ago, 07:35 AM
HUTCHMED shares are trading higher after the company announced high-level results from the SAFFRON Phase III trial.
- StockTitan · 1 day ago, 11:00 AM
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® | HCM Stock News
- Tip Ranks · Aug 6 at 07:27 PM
HUTCHMED (China) (HCM) Gets a Buy from CICC
- Tip Ranks · Aug 3 at 07:27 PM
UOB Kay Hian Remains a Buy on HUTCHMED (China) (HCM)
